Arbutus Biopharma Corporation Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ABUS, updated each market day.
ABUS AI Sentiment
AI sees no strong directional signal for Arbutus Biopharma Corporation Common Stock stock over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Arbutus Biopharma Corporation Common Stock
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Sector
Exchange
Market Cap
$1,004,396,117
Cap Tier
Employees
19
Headquarters
WARMINSTER, PA
Listed Since
July 26, 2007
Website
ABUS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ABUS Volatility
Arbutus Biopharma Corporation Common Stock has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
